Related Experiment Video
Updated: Jun 4, 2026
06:16
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
ETC-216 for coronary artery disease
Stephen J Nicholls1, Kiyoko Uno, Yu Kataoka
1Heart & Vascular Institute, Cleveland Clinic, Department of Cardiovascular Medicine, Cleveland, OH 44195, USA. nichols1@ccf.org
Expert Opinion on Biological Therapy
|January 29, 2011
Summary
Apolipoprotein A-I(Milano) (AIM), a modified high-density lipoprotein (HDL), shows promise in reducing cardiovascular risk. Further trials are needed to confirm its impact on cardiovascular events.
Area of Science:
- Cardiovascular medicine
- Lipoprotein research
- Pharmacology
Background:
- High-density lipoprotein (HDL) function is increasingly recognized as a target for cardioprotection.
- Apolipoprotein A-I(Milano) (AIM) is a variant of the major HDL protein with potential therapeutic benefits.
- Early evidence supports AIM's development for reducing cardiovascular risk.
Purpose of the Study:
- To review the importance of HDL as a therapeutic target.
- To examine early data on the beneficial effects of AIM.
- To assess the clinical evidence for AIM in cardiovascular disease.
Main Methods:
- Literature review of clinical studies on AIM.
- Analysis of PubMed-indexed studies.
- Evaluation of existing data on HDL function and AIM.
Main Results:
- HDL is a key target for cardioprotective strategies.
- AIM demonstrates beneficial activities relevant to cardiovascular health.
- Clinical studies indicate AIM's potential in managing cardiovascular risk.
Conclusions:
- ETC-216, a lipid-deplete HDL containing recombinant AIM, promotes rapid regression of coronary atherosclerosis.
- Further clinical trials are essential to evaluate ETC-216's impact on cardiovascular events.
- AIM-based therapies require additional investigation before clinical implementation.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...